HealthMore in Health→
Favipiravir Trial Points to a New Treatment Option for Lassa Fever
Key Takeaways
- A Nigerian phase 2 trial randomized 41 adults with mild-to-moderate Lassa fever to favipiravir or ribavirin.
- The study met its primary pharmacokinetic, safety and tolerability endpoints for favipiravir.
- Drug-related adverse events were evenly distributed between the two treatment arms.
- Larger trials are still needed to determine whether favipiravir improves clinical outcomes.
DE
DT Editorial Team··via nature.com